ABBOTT LABORATORIES (ABT)

Abbott Laboratories is an Illinois corporation, incorporated in 1900, engaged in the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products worldwide. The company operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment markets branded generic pharmaceuticals outside the United States, primarily in emerging markets, covering therapeutic areas such as gastroenterology, women's health, cardiovascular and metabolic conditions, pain and central nervous system disorders, respiratory drugs and vaccines, and biosimilars.

The Diagnostic Products segment offers diagnostic systems and tests globally, including core laboratory and transfusion medicine systems (Alinity, ARCHITECT, Cell-Dyn), molecular diagnostics, point-of-care testing (i-STAT), rapid diagnostics (BinaxNOW, ID NOW), and informatics/automation solutions, serving blood banks, hospitals, laboratories, and other healthcare entities. The Nutritional Products segment provides pediatric and adult nutritional products worldwide, including well-known brands like Similac, Ensure, Glucerna, and PediaSure, sold to consumers, institutions, and retailers. The Medical Devices segment offers a broad range of products for cardiovascular disease treatment (rhythm management, electrophysiology, heart failure, vascular, and structural heart devices), diabetes care (FreeStyle Libre continuous glucose monitoring), and neuromodulation devices for chronic pain and movement disorders, sold globally through direct sales and distributors.

Abbott holds a large portfolio of patents and trademarks, with none deemed individually material to the business. The company faces competition based on innovation, price, and product performance across all segments, and its operations are subject to extensive regulation by the FDA and international regulatory agencies, covering areas from product approval to marketing, pricing, and data privacy. As of December 31, 2024, Abbott employed approximately 114,000 people globally, with 69% located outside the U.S., and maintains a strong focus on diversity, employee development, and compensation equity.

The company's stock trades on the NYSE, with an aggregate market value of nonaffiliate shares at approximately $177.1 billion as of June 28, 2024, and about 1.73 billion common shares outstanding as of January 31, 2025. Abbott operates in more than 160 countries and continues to navigate a complex global regulatory and healthcare policy environment affecting pricing, reimbursement, and product development.